saids vaccines

Summary

Summary: Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.

Top Publications

  1. pmc Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
    Scott G Hansen
    Vaccine and Gene Therapy Institute, Department of Molecular Microbiology, Oregon Health and Science University, Beaverton, Oregon 97006, USA
    Nature 473:523-7. 2011
  2. pmc Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 482:89-93. 2012
  3. pmc Macaques vaccinated with live-attenuated SIV control replication of heterologous virus
    Matthew R Reynolds
    AIDS Vaccine Research Laboratory, Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI 53715, USA
    J Exp Med 205:2537-50. 2008
  4. pmc Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
    Brandon F Keele
    University of Alabama at Birmingham, Birmingham, AL 35223, USA
    J Exp Med 206:1117-34. 2009
  5. pmc Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine
    Lilin Lai
    Yerkes National Primate Research Center, USA
    J Infect Dis 204:164-73. 2011
  6. pmc Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge
    Matthew R Reynolds
    AIDS Vaccine Research Laboratory, 555 Science Dr, Madison, WI 53711, USA
    J Virol 84:9190-9. 2010
  7. pmc Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques
    Andreas Mörner
    Vaccinology Unit, Swedish Institute for Communicable Disease Control, S 171 82 Solna, Sweden
    J Virol 85:6442-52. 2011
  8. pmc Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine
    Huma Qureshi
    Center for Comparative Medicine, University of California, Davis, California, USA
    J Virol 86:2239-50. 2012
  9. ncbi Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers
    Nami Iwamoto
    International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    AIDS 24:2777-87. 2010
  10. ncbi Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation
    Regina Hofmann-Lehmann
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    AIDS 17:157-66. 2003

Detail Information

Publications191 found, 100 shown here

  1. pmc Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
    Scott G Hansen
    Vaccine and Gene Therapy Institute, Department of Molecular Microbiology, Oregon Health and Science University, Beaverton, Oregon 97006, USA
    Nature 473:523-7. 2011
    ..Thus, persistent vectors such as CMV and their associated T(EM) responses might significantly contribute to an efficacious HIV/AIDS vaccine...
  2. pmc Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 482:89-93. 2012
    ..These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys...
  3. pmc Macaques vaccinated with live-attenuated SIV control replication of heterologous virus
    Matthew R Reynolds
    AIDS Vaccine Research Laboratory, Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI 53715, USA
    J Exp Med 205:2537-50. 2008
    ....
  4. pmc Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
    Brandon F Keele
    University of Alabama at Birmingham, Birmingham, AL 35223, USA
    J Exp Med 206:1117-34. 2009
    ..These findings identify key similarities in mucosal transmission and early diversification between SIV and HIV-1, and thus validate the SIV-macaque mucosal infection model for HIV-1 vaccine and microbicide research...
  5. pmc Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine
    Lilin Lai
    Yerkes National Primate Research Center, USA
    J Infect Dis 204:164-73. 2011
    ..The prevention of infection showed a strong correlation with the avidity of the elicited Env-specific antibody for the Env of the SIVsmE660 challenge virus (r = 0.9; P < .0001)...
  6. pmc Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge
    Matthew R Reynolds
    AIDS Vaccine Research Laboratory, 555 Science Dr, Madison, WI 53711, USA
    J Virol 84:9190-9. 2010
    ..Overall, our results suggest that a well-designed HIV vaccine might both reduce the rate of acquisition and control viral replication...
  7. pmc Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques
    Andreas Mörner
    Vaccinology Unit, Swedish Institute for Communicable Disease Control, S 171 82 Solna, Sweden
    J Virol 85:6442-52. 2011
    ..This study demonstrates that immunization with recombinant HLA in combination with HIV-1 antigens might be developed into an alternative strategy for a future AIDS vaccine...
  8. pmc Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine
    Huma Qureshi
    Center for Comparative Medicine, University of California, Davis, California, USA
    J Virol 86:2239-50. 2012
    ..Further studies are necessary to confirm the enhancement of virus acquisition and to discern associated mechanisms...
  9. ncbi Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers
    Nami Iwamoto
    International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    AIDS 24:2777-87. 2010
    ..These animals allowed viremia in the acute phase but showed persistent viral control after the setpoint. Here, we examined the breadth of postchallenge virus-specific cellular immune responses in these SIV controllers...
  10. ncbi Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation
    Regina Hofmann-Lehmann
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    AIDS 17:157-66. 2003
    ..In the present study, we demonstrate that SIVmac239Delta3 is pathogenic in most vaccinated adult monkeys, given enough time...
  11. pmc Risk of immunodeficiency virus infection may increase with vaccine-induced immune response
    Matthias Tenbusch
    Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
    J Virol 86:10533-9. 2012
    ..The results are consistent with the hypothesis that virus-specific T helper cells mediate this detrimental effect and contribute to the inefficacy of past HIV vaccination attempts (e.g., STEP study)...
  12. pmc Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques
    Myrna C Bonaldo
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, 555 Science Dr, Madison, WI 53711, USA
    J Virol 84:3699-706. 2010
    ..These recombinant YF17D-induced SIV-specific CD8(+) T cells secreted several cytokines, were largely effector memory T cells, and suppressed viral replication in CD4(+) T cells...
  13. pmc DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge
    Margherita Rosati
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Proc Natl Acad Sci U S A 106:15831-6. 2009
    ..These results demonstrate that DNA vaccination in the absence of any heterologous boost can provide protection from high viremia comparable to any other vaccine modalities tested in this macaque model...
  14. pmc Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6
    M Genesca
    Center for Comparative Medicine, California National Primate Research Center, University of California, Davis, CA 95616, USA
    J Intern Med 265:67-77. 2009
    ....
  15. pmc Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus
    Christopher J Miller
    Center for Comparative Medicine, University of California Davis, Davis, CA 95616, USA
    J Virol 79:9217-27. 2005
    ....
  16. pmc Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques
    Peng Xiao
    NIH, NCI, 41 Medlars Drive, Building 41, Room D804, Bethesda, MD 20892 5065, USA
    J Virol 84:7161-73. 2010
    ..Overall, the replicating Ad5hr-HIV/SIV priming/gp140 protein boosting approach elicited strong systemic and mucosal antibodies with multiple functional activities associated with control of both acute and chronic viremia...
  17. pmc Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen
    John B Schell
    Yale University School of Medicine, 310 Cedar St, New Haven, CT 06510, USA
    J Virol 85:5764-72. 2011
    ..Although the immune correlates of protection are not yet clear, the heterologous VSV/SFVG prime-boost is clearly a potent vaccine regimen for inducing virus nAbs and protection against a heterogeneous viral swarm...
  18. pmc CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus
    Richard Stebbings
    Division of Immunology, NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
    J Virol 79:12264-72. 2005
    ....
  19. pmc Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques
    Rachmat Hidajat
    Vaccine Branch, National Cancer Institute, Bethesda, Maryland 20892 5065, USA
    J Virol 83:791-801. 2009
    ..The pattern of elevated immune responses in the I/O group is consistent with its better control of acute viremia mediated, at least in part, by ADCVI activity and transcytosis inhibition...
  20. pmc High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cytometry A 79:603-12. 2011
    ....
  21. pmc Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting
    L Jean Patterson
    Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:2212-21. 2004
    ..This combination prime-boost strategy, utilizing replication competent adenovirus, is a promising alternative for HIV vaccine development...
  22. ncbi An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
    N F Rose
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Cell 106:539-49. 2001
    ..Protection from AIDS was highly significant (p = 0.001). VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection...
  23. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  24. pmc Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge
    Danilo R Casimiro
    Department of Vaccines Basic Research, Merck Research Laboratories, Merck and Co, West Point, Pennsylvania 19486, USA
    J Virol 84:2996-3003. 2010
    ..The implications of these results in light of the recent discouraging results of the phase IIb study of the trivalent Ad5 HIV-1 vaccine are discussed...
  25. pmc Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon respon
    Kristina Abel
    Center for Comparative Medicine, California National Primate Research Center, School of Veterinary Medicine, University of California Davis, California 95616, USA
    J Virol 77:3099-118. 2003
    ..Thus, innate as well as cellular anti-SIV immune responses appeared to contribute to the SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239...
  26. pmc Novel biopanning strategy to identify epitopes associated with vaccine protection
    Barbara C Bachler
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Virol 87:4403-16. 2013
    ..PL biopanning is also unbiased with regard to pathogens or disease model, making it a universal tool...
  27. pmc A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge
    Matthew R Reynolds
    AIDS Vaccine Research Laboratory, 555 Science Drive, Madison, WI 53711, USA
    Vaccine 30:4465-75. 2012
    ..Our results are consistent with those observed in the Step trial and indicate that SIV immunization and challenge studies in macaque models of HIV infection can be informative in assessing pre-clinical HIV vaccines...
  28. ncbi Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies
    Erik Rollman
    Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
    J Immunol 179:4571-9. 2007
    ..The delayed cytolytic phenotype exhibited by standard vector-based vaccine-induced CTLs may limit the ability of T cell-based HIV vaccines to rapidly control acute infection following a pathogenic lentiviral exposure...
  29. pmc Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates
    Lukas Flatz
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:7760-70. 2012
    ..These data indicate that a vaccine expressing a mismatched Env gene alone can prevent SIV infection in NHPs and identifies an immune correlate that may guide immunogen selection and immune monitoring for clinical efficacy trials...
  30. pmc Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV
    Chie Sugimoto
    AIDS Research Center, National Institute of Infectious Diseases, Shinjuku ku, Tokyo, Japan
    PLoS ONE 5:e11678. 2010
    ..In summary, results of this study indicate that deglycosylated live-attenuated vaccines may provide a platform for the elucidation of correlates of protection needed for a successful HIV vaccine against diverse isolates...
  31. pmc SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses
    Lilin Lai
    Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States
    Vaccine 30:1737-45. 2012
    ..The simian vaccines and regimens represent prototypes for candidate HIV vaccines currently undergoing clinical testing...
  32. pmc Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    Xiaoping Liang
    Merck Research Laboratories, P O Box 4, WP16 306, West Point, PA 19486, USA
    J Virol 79:12321-31. 2005
    ..The implications of these results in the development of an HIV-1 vaccine will be discussed...
  33. ncbi Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara
    Mariana Manrique
    Department of Medicine, Children s Hospital, Boston, MA 02115, USA
    J Immunol 186:3581-93. 2011
    ..Postchallenge immunological correlates of protection were systemic anti-SIV Gag + Env CD4(+)/IL-2(+), CD4(+)/IFN-γ(+), and CD8(+)/TNF-α(+) T cells and vaginal anti-SIV Gag + Env CD8(+) T cell total monofunctional responses...
  34. pmc Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus
    Klara Tenner-Racz
    Department of Pathology and Koerber Laboratory for AIDS Research, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany
    Proc Natl Acad Sci U S A 101:3017-22. 2004
    ..Therefore, during tonsillar SIV Delta nef vaccination, infection is blocked early at the entry portal, which we propose is due in part to innate functions of gamma delta T and dendritic cells...
  35. ncbi PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination
    Adam C Finnefrock
    Vaccine Basic Research, Merck Research Laboratories, West Point, PA 19486, USA
    J Immunol 182:980-7. 2009
    ..05) increase in the peak percentage of T cells specific for the CM9 Gag epitope. These new results on PD-1 blockade in nonhuman primates point to a broader role for PD-1 immunomodulation and to potential applications in humans...
  36. ncbi SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques
    Jean D Boyer
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Med Primatol 34:262-70. 2005
    ..The vaccine immune responses contained both a CD8 component as well a CD4 component. The adjuvanted DNA vaccines illustrate that IL-12 enhances a CD8 vaccine immune response, however, different cellular profiles...
  37. ncbi Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses
    Nina V Malkevitch
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, 41 Medlars Drive MSC 5065, Building 41, Room D804, Bethesda, MD 20892 5065, USA
    Virology 353:83-98. 2006
    ..Overall, cellular immunity induced by vaccination and/or low-level, inapparent viremia post-first SIV(mac251) challenge, was associated with durable protection against re-challenge...
  38. pmc Relevance of studying T cell responses in SIV-infected rhesus macaques
    Laura E Valentine
    Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, 53711 USA
    Trends Microbiol 16:605-11. 2008
    ..The best animal model available to explore such issues is simian immunodeficiency virus infection of rhesus macaques, which serves as the primary proving ground for AIDS vaccines...
  39. pmc Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination
    Vijayakumar Velu
    Vaccine Research Center, Department of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    J Virol 81:5819-28. 2007
    ....
  40. ncbi Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges
    Robert A Rasmussen
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS 21:1841-8. 2007
    ..To determine whether multigenic protein immunogens including native, trimeric HIV clade C (HIV-C) gp160 could cross-protect macaques against mucosal challenge with clade C (SHIV-C) mismatched for env...
  41. ncbi Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques
    Ussama M Abdel-Motal
    New England Primate Research Center, Harvard Medical School, Southborough, MA 01772, USA
    Virology 333:226-38. 2005
    ....
  42. ncbi Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy
    M Shimada
    Department of Molecular Biodefence Research, Graduate School of Medicine, Yokohama City University, Kanazawa Ku, Yokohama, Japan
    Gene Ther 16:218-28. 2009
    ..These results suggest that vaccination can improve antiviral cell-mediated and humoral immunity, which may contribute to controlling viral replication...
  43. pmc Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge
    Nancy A Wilson
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, Madison, Wisconsin 53711, USA
    J Virol 83:6508-21. 2009
    ....
  44. pmc Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys
    Norman L Letvin
    Vaccine Research Center, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    J Virol 78:7490-7. 2004
    ....
  45. pmc Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen
    Jun Zhao
    Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:8354-65. 2003
    ..The results suggest that a spectrum of immune responses may be necessary for adequate control of viral replication and disease progression and highlight a potential role for nonneutralizing antibodies at mucosal sites...
  46. pmc Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit
    Antonio Valentin
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702 1201, United States
    Vaccine 28:1962-74. 2010
    ..Therefore, these data support the concept of adding DNA vaccination to the HAART regimen to boost the HIV-specific immune responses...
  47. pmc Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers
    Konstantin Virnik
    Lab of Immunoregulation, Division of Viral Products, Office of Vaccines, Center for Biologics, FDA, NIH Campus, Bethesda, MD 20892, USA
    Vaccine 30:5453-8. 2012
    ..Rubella readily infects rhesus macaques, and these animals will provide an ideal model for testing the new vectors for replication in vivo, immunogenicity, and protection against SIV or SHIV challenge...
  48. ncbi Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions
    Konstantin Virnik
    Lab of Immunoregulation, Division of Viral Products, Office of Vaccines, Center for Biologics, FDA, Bldg 29, Room 523, NIH Campus, Bethesda, MD 20892, United States
    Vaccine 31:2119-25. 2013
    ..The rubella vaccine strain readily infects rhesus macaques, and these animals will be the model of choice for testing vector growth in vivo and immunogenicity...
  49. pmc Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques
    V Traina-Dorge
    Division of Microbiology, Tulane National Primate Research Center, Covington, LA 70433, United States
    Vaccine 28:6483-90. 2010
    ....
  50. pmc Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 82:4844-52. 2008
    ..Moreover, qualitative differences in cellular immune responses may prove critical in determining the overall potency of heterologous rAd prime-boost regimens...
  51. pmc Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge
    Michael D Alpert
    Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, One Pine Hill Drive, Southborough, MA 01772 9102, USA
    J Virol 84:10748-64. 2010
    ....
  52. pmc Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys
    Yang Ou
    Department of Microbiology and Immunology, Slot 511, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Virology 364:291-300. 2007
    ..The rSVV established latent infection in neural ganglia. A subsequent study will evaluate the ability of rSVV vaccines expressing SIV antigens to protect nonhuman primates against simian AIDS...
  53. pmc A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques
    Jan zur Megede
    Novartis Vaccines and Diagnostics Inc, Emeryville, California, USA
    AIDS Res Hum Retroviruses 24:1103-16. 2008
    ..However, plasma RNA viral loads rebounded after ART termination to similar levels in all three groups, but remained below 10(5) copies/ml until the end of the study, which could be a late effect of the triple drug therapy...
  54. ncbi Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques
    Deborah Heydenburg Fuller
    PowderJect Vaccines Inc, Madison, WI 53562, USA
    Virology 364:245-55. 2007
    ..These data demonstrate that immunization with hybrid HBcAg-epitope DNA vaccines is an effective strategy to increase the magnitude and breadth of HIV-specific CTL responses...
  55. pmc Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251
    Koen K A Van Rompay
    California National Primate Research Center, University of California, Davis 95616, USA
    J Virol 77:179-90. 2003
    ....
  56. pmc Plasmodium inui infection reduces the efficacy of a simian immunodeficiency virus DNA vaccine in a rhesus macaque model through alteration of the vaccine-induced immune response
    Jiangmei Yin
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Infect Dis 206:523-33. 2012
    ..This study demonstrated that P. inui infection had an influence on the immune response to an SIV DNA vaccine and decreased the vaccine's efficacy...
  57. ncbi Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    R R Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, GA 30329, USA
    Science 292:69-74. 2001
    ..These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic...
  58. ncbi Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation
    Margherita Rosati
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702 1201, United States
    Vaccine 26:5223-9. 2008
    ..These results indicate that improved gene delivery and expression by electroporation dramatically increases immunogenicity of DNA vaccines. Electroporation is thus an important method to improve the effectiveness of DNA vaccination...
  59. pmc Immunity and protection by live attenuated HIV/SIV vaccines
    Dominik Wodarz
    Department of Ecology and Evolution, 321 Steinhaus Hall, University of California, Irvine CA 92697, USA
    Virology 378:299-305. 2008
    ..According to these arguments, an inverse correlation between the level of attenuation and the level of protection is expected, and this has indeed been observed in experimental data...
  60. pmc Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Virol 83:9584-90. 2009
    ..Inclusion of Env resulted in improved control of peak and set point SIV RNA levels following challenge. In contrast, DNA vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system...
  61. pmc Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques
    Thomas M Yankee
    Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, 3025 WHW MS 3029, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Virology 383:103-11. 2009
    ....
  62. pmc With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus
    Meritxell Genesca
    CNPRC, UC Davis, One Shields Ave, Davis, CA 95616, USA
    J Virol 82:11181-96. 2008
    ....
  63. ncbi Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  64. pmc Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo
    Justin M Greene
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, 585 Science Drive, Madison, WI 53711, USA
    J Virol 84:3362-72. 2010
    ..Moreover, these results underscore the limitations of relying on immunological measurements from peripheral blood lymphocytes in studies of protective immunity to HIV/SIV...
  65. ncbi Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251
    V Rául Gómez-Román
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2185-9. 2005
    ..Our findings expose ADCC activity as an immune correlate that may be relevant in the rational design of an efficacious vaccine against HIV...
  66. ncbi Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
    You S Suh
    Department of Virology and Immunology, German Primate Center, Gottingen, Germany
    Vaccine 24:1811-20. 2006
    ..These results indicate that the multigenic DNA prime-adenovirus boost immunization may be a promising approach in developing an effective AIDS vaccine...
  67. pmc Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine
    Deborah Heydenburg Fuller
    PowderJect Vaccines, Inc, Madison, Wisconsin 53711, USA
    J Virol 76:3309-17. 2002
    ..These results support further development of a DNA vaccine for protection against HIV...
  68. pmc Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization
    Agneta S von Gegerfelt
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, 1050 Boyles Street, Building 535, Room 210, Frederick, MD 21702 1201, USA
    J Virol 81:1972-9. 2007
    ..Several animals show a long-lasting decrease in viremia, suggesting that therapeutic vaccination may provide an additional benefit to antiretroviral therapy...
  69. pmc Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein
    Silvija I Staprans
    Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30329, USA
    Proc Natl Acad Sci U S A 101:13026-31. 2004
    ..These data suggest suggest that candidate AIDS vaccines may not simply be either efficacious or neutral; they may also have the potential to be harmful...
  70. pmc T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge
    Mauricio A Martins
    Department of Pathology and Laboratory Medicine, University of Wisconsin Madison, 555 Science Dr, Madison, WI 53711, USA
    J Virol 84:4352-65. 2010
    ..Furthermore, the present study demonstrates that certain viral proteins may be more effective than others as vaccine immunogens...
  71. pmc Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239
    Thorsten U Vogel
    Wisconsin Primate Research Center Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53715, USA
    J Virol 77:13348-60. 2003
    ....
  72. ncbi Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy
    Elzbieta Tryniszewska
    Basic Research Laboratory, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 169:5347-57. 2002
    ..These data provide the proof of concept that therapeutic vaccination before cessation of ART may be a feasible approach in the clinical management of HIV-1 infection...
  73. ncbi Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8)
    Neil Berry
    Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    J Gen Virol 89:2240-51. 2008
    ..The role of innate and intrinsic anti-retroviral immunity in the protection conferred by live attenuated SIV vaccines warrants careful study...
  74. pmc Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
    Atze T Das
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam CINIMA, Academic Medical Center of the University of Amsterdam, The Netherlands
    Retrovirology 5:44. 2008
    ..Since macaque studies will likely require an efficiently replicating variant, we set out to optimize SIV-rtTA through in vitro viral evolution...
  75. pmc Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys
    Norman L Letvin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 312:1530-3. 2006
    ..These immune correlates of vaccine efficacy should guide the evaluation of AIDS vaccines in humans...
  76. pmc Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
    R P Johnson
    Division of Immunology, New England Regional Primate Research Center, Harvard Medical School, Southborough, Massachusetts 01772, USA
    J Virol 71:7711-8. 1997
    ....
  77. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  78. pmc Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression follow
    Helen Horton
    Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, Wisconsin 53715, USA
    J Virol 76:7187-202. 2002
    ..01). However, despite the induction of virus-specific cellular immune responses and reduced peak viral loads, most animals still suffered from gradual CD4 depletion and progressed to disease...
  79. ncbi A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques
    Karuppiah Muthumani
    Department of Pathology and Laboratory of Medicine, University of Pennsylvania, 505 Stellar Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104, USA
    Vaccine 21:629-37. 2003
    ..Furthermore, vaccinated animals exhibited protection against CD4(+) T-cell loss...
  80. ncbi Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV
    Bapi Pahar
    Tulane National Primate Research Center, Covington, LA 70433, USA
    Vaccine 24:6839-49. 2006
    ..We predict that if coadministered with additional epitopes and/or more efficacious mucosal delivery system or route, HIV/SIV-derived peptide vaccines may have potential to elicit heterologous protection...
  81. ncbi Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge
    R K Ahmed
    Swedish Institute for Infectious Disease Control, Solna
    J Gen Virol 80:1569-74. 1999
    ..The results indicate that beta-chemokines may play a role in protective immunity but also that genetic and/or environmental factors may influence their production...
  82. pmc Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
    M A Egan
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 74:7485-95. 2000
    ..These observations suggest that plasmid DNA may prove a useful component of a human immunodeficiency virus type 1 vaccine...
  83. pmc Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques
    Adrian B McDermott
    Wisconsin National Primate Center, 1220 Capitol Court, Madison, WI 53715, USA
    J Virol 79:15556-66. 2005
    ..These results suggest that viral "breakthrough" in vaccinated animals and viral escape are not inextricably linked and underscore the need for additional research into the mechanisms of vaccine failure...
  84. pmc Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine
    Yichuan Wang
    Center for Comparative Medicine, University of California, Davis, 95616, USA
    Clin Vaccine Immunol 16:499-505. 2009
    ..The lack of benefit may be related to the high levels of SIV-specific lymphocyte proliferation in the CpG adjuvant group...
  85. ncbi Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus
    C Stahl-Hennig
    German Primate Centre, Goettingen, Germany
    J Gen Virol 77:2969-81. 1996
    ..Nevertheless, such a vaccine raises severe safety concerns because of its potential to revert to virulence...
  86. pmc Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239
    Panagiotis Vagenas
    Center for Biomedical Research, HIV AIDS Program, Population Council, New York, NY, USA
    J Acquir Immune Defic Syndr 52:433-42. 2009
    ....
  87. pmc Impact of MHC class I diversity on immune control of immunodeficiency virus replication
    Philip J R Goulder
    Department of Paediatrics, Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
    Nat Rev Immunol 8:619-30. 2008
    ..Here, we review recent studies of T-cell-mediated control of HIV and SIV infection, and offer insight for the design of a successful T-cell-based HIV vaccine in the future...
  88. pmc Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery
    Keith Mansfield
    New England Primate Research Center, Harvard Medical School, One Pine Hill Drive, Box 9102, Southborough, MA 01772 9102, USA
    J Virol 82:4135-48. 2008
    ....
  89. ncbi Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant
    Chie Sugimoto
    AIDS Research Center, National Institute of Infectious Diseases, Shinjuku ku, Tokyo 162 8640, Japan
    J Gen Virol 89:554-66. 2008
    ....
  90. pmc Atraumatic oral spray immunization with replication-deficient viral vector vaccines
    Christiane Stahl-Hennig
    Department of Virology and Immunology, German Primate Centre, Gottingen, Germany
    J Virol 81:13180-90. 2007
    ....
  91. ncbi A single vaccination with attenuated SIVmac 239 via the tonsillar route confers partial protection against challenge with SIVmac 251 at a distant mucosal site, the rectum
    Christiane Stahl-Hennig
    German Primate Center, D 37077 Gottingen, Germany
    Front Biosci 12:2107-23. 2007
    ..Therefore, tonsillar application of attenuated SIV induces protection in some animals against a superinfection with wild-type SIV distant at a distant mucosal site...
  92. pmc Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques
    L Mortara
    Institut Cochin de Génétique Moléculaire ICGM, Laboratoire d Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445 Université René Descartes, Hopital Cochin, 75014 Paris
    J Virol 73:4447-51. 1999
    ..These results show the importance of a strong specific type 1 Th response for inducing a multispecific CTL response in vivo, which is essential for the development of an anti-human immunodeficiency virus vaccine...
  93. ncbi Therapeutic dendritic-cell vaccine for simian AIDS
    Wei Lu
    Institut de Recherche sur les Vaccins et l Immunothérapie des cancers et du SIDA, Paris, France
    Nat Med 9:27-32. 2003
    ..Neutralizing antibody responses were augmented and remained elevated. Inactivated whole virus-pulsed dendritic cell vaccines are promising means to control diseases caused by immuno- deficiency viruses...
  94. ncbi Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine
    Atze T Das
    Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    Expert Rev Vaccines 1:293-301. 2002
    ..We propose a conditional live virus, of which the replication can be switched on and off at will, as a novel approach for an HIV vaccine...
  95. ncbi Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines
    Seraphin Kuate
    Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
    Virology 313:653-62. 2003
    ....
  96. ncbi DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication
    Jean D Boyer
    Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA
    Virology 333:88-101. 2005
    ..monocytogenes can induce a cellular immune response in a nonhuman primate and is able to enhance the efficacy of a DNA vaccine as well as provide modest protection against SIV239 challenge...
  97. ncbi Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV
    Koen K A Van Rompay
    California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA
    J Acquir Immune Defic Syndr 38:124-34. 2005
    ..The results of these investigations suggest that immunization of human infants with poxvirus-based HIV vaccine candidates may offer protection against early and late HIV infection through breastfeeding...
  98. pmc Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques
    Brian J Rybarczyk
    Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Virol 78:3561-71. 2004
    ..This result suggests that diversification of the SIV env V1/V2 region is the result of a type-specific antibody response...
  99. pmc Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239
    Nancy A Wilson
    Wisconsin National Primate Research Center, University of Wisconsin Madison, Madison, WI 53711, USA
    J Virol 80:5875-85. 2006
    ....
  100. ncbi CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells
    Natalia Teleshova
    Center for Biomedical Research, Population Council, New York, NY 10021, USA
    J Immunol 173:1647-57. 2004
    ....
  101. ncbi Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
    Dan H Barouch
    Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Research East Room 113, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 415:335-9. 2002
    ..These data indicate that viral escape from CTL recognition may be a major limitation of the CTL-based AIDS vaccines that are likely to be administered to large human populations over the next several years...

Research Grants62

  1. Targeting mTOR and CD40 Pathways for Adjuvanting HIV Vaccines
    Rama Rao Amara; Fiscal Year: 2013
    ..Thus, there is a great need to develop a safe and effective HIV vaccine that provides a low-cost, low-toxicity solution to long-term control of viral replication - the main goal of this PPG. ..
  2. Mechanisms of mucosal protection by HPV-SIV and gp96-lg-SIV vaccines
    Eckhard R Podack; Fiscal Year: 2011
    ..The combination of the two vaccines offers the potential of comprehensive immune activation in the mucosa providing enhanced resistance to SIV infection. ..
  3. Primate Core Immunology - Virol. Lab.: Humoral Imm. Lab.
    David Montefiori; Fiscal Year: 2011
    ..b. Develop and conduct assays to evaluate functional humoral immune responses (such as virus neutralization assays as described above) in mucosal secretions or mucosal tissues from immunized and/or infected macaques. ..
  4. Primate Core Immunology - Virol. Lab. - PART B: Humoral Imm. Lab.
    David Montefiori; Fiscal Year: 2009
    ..b. Develop and conduct assays to evaluate functional humoral immune responses (such as virus neutralization assays as described above) in mucosal secretions or mucosal tissues from immunized and/or infected macaques...
  5. IMMUNE RESPONSES TO CLYCOSYLATION-MODIFIED SIV VACCINES
    David Montefiori; Fiscal Year: 1993
    ..These studies are viewed as the first phase of a larger effort aimed at adequately addressing potential hazards and benefits that may be created by modifying normal glycosylation of potential SIV and HIV vaccines...
  6. PATHOGENIC CONVERSION OF ATTENUATED SIV VACCINES
    Earl Sawai; Fiscal Year: 2003
    ..Accordingly, the proposed studies will provide critical insight into molecular changes in the viral genome that are necessary for pathogenic conversion of live-attenuated viral vaccines. ..
  7. DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION
    Ronald Montelaro; Fiscal Year: 2004
    ..abstract_text> ..
  8. NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES
    Mark Feinberg; Fiscal Year: 2003
    ..An Administrative and Data Management Core will coordinate the HIVRAD projects and facilitate communication of ideas and experimental results between investigators. ..
  9. MAO/DETECTION OF ANTIBODIES & PROTEINS--ISOLATION OF VIR
    Ranajit Pal; Fiscal Year: 1999
    ..In addition, the Category E contractors will provide facilities and equipment to conduct biosafety level 2 or 3 laboratory work. ..
  10. HIV and SIV Vaccines and Mucosal Immunity
    Anna Aldovini; Fiscal Year: 2005
    ..The results of this investigation should be important not only for AIDS vaccine development but also for the development of DNA vaccines for other mucosal pathogens. ..
  11. Potentiation Immune Resp vs HIV vacc Modula Innate Resp
    Murali Krishna Kaja; Fiscal Year: 2002
    ....
  12. NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS
    Sampa Santra; Fiscal Year: 2012
    ..abstract_text> ..
  13. NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS
    Norman Letvin; Fiscal Year: 2011
    ..abstract_text> ..
  14. NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS
    Sampa Santra; Fiscal Year: 2013
    ..abstract_text> ..
  15. Immunostimulatory single cycle SIV Vaccines incorporating TRAF-mediated molecular
    GEOFFREY STONE; Fiscal Year: 2009
    ..The result of these studies will establish whether attenuated HIV vaccines can be boosted using key components of the mammalian immune system or viral mimics of these molecules. ..
  16. DEVELOPMENT OF AN AIDS PROTOTYPE VACCINE USING SIV
    Michael Murphey Corb; Fiscal Year: 1993
    ....
  17. MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MOD
    RANDALL OWENS; Fiscal Year: 1999
    ..The category B contractor will maintain a data base for each study they are conducting in order to follow the immunization protocol, virus challenge, and all the assay results for each monkey in the study. ..
  18. MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE
    RICHARD BRADBURY; Fiscal Year: 2000
    ..The category B contractors will maintain a data base for each study they are conducting n order to follow the immunization protocol, virus challenge, and all the assay results for each monkey in the study. ..
  19. EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS
    Philip Johnson; Fiscal Year: 2000
    ..The category B contractors will maintain a data base for each study they are conducting in order to follow the immunization protocol, virus challenge, and all the assay results for each monkey in the study. ..
  20. NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LAB AIDS VACCINE R&D
    David Montefiori; Fiscal Year: 2012
    ..abstract_text> ..
  21. MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE
    RICHARD BRADBURY; Fiscal Year: 2000
    ..The category B contractors will maintain a data base for each study they are conducting in order to follow the immunization protocol, virus challenge, and all the assay results for each monkey in the study. ..
  22. NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LAB AIDS VACCINE R&D
    David Montefiori; Fiscal Year: 2011
    ..abstract_text> ..
  23. NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LAB AIDS VACCINE R&D
    David Montefiori; Fiscal Year: 2013
    ..abstract_text> ..
  24. TAS::75 0885::TAS NONHUMAN PRIMATE CORE CELLULAR IMMUNOLOGY LABORATORY FOR AIDS
    Norman Letvin; Fiscal Year: 2010
    ..abstract_text> ..
  25. INTEGRATED PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT
    Jiri Mestecky; Fiscal Year: 2002
    ..J. Mestecky, P.I., UAB)> Immunization strategies that induce mucosal and systemic humoral and cellular immune responses will be investigated in humans with particular emphasis on the immune system of the male genital tract. ..
  26. LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS
    Ronald Desrosiers; Fiscal Year: 2004
    ..Through these experiments we will begin the understand the mechanisms of protective immunity and what is needed to induce it. ..
  27. Passive-Active Vaccine Strategies Against Pediatric AIDS
    Marta Marthas; Fiscal Year: 2004
    ..abstract_text> ..
  28. INDUCTION OF MUCOSAL IMMUNITY WITH RECOMBINANT VACCINES
    Tilahun Yilma; Fiscal Year: 2002
    ..Since the mucosal route is the most common route of transmission of HIV, these animals will be challenged intravaginally to evaluate the efficacy of the vaccines. ..
  29. IMMUNOLOGIC MECHANISMS CONTROLLING SIV REPLICATION
    Keith Reimann; Fiscal Year: 2002
    ....
  30. Effect of Microbicides on Mucosal HIV Transmission
    Christopher Miller; Fiscal Year: 2004
    ..Further, these studies will determine if individuals that consistently and correctly use of microbicides in the face of repeated viral exposure develop anti-viral immune responses or local infection. ..
  31. ANNUAL SYMPOSIUM ON NONHUMAN PRIMATE MODELS FOR AIDS
    Christopher Miller; Fiscal Year: 2002
    ..There will also be an evening banquet at the Monterey Bay Aquarium. ..
  32. DNA VACCINE IMMUNITY TO HIV1 AND SIV
    Norman Letvin; Fiscal Year: 2002
    ..This aim therefore studies cross reactivity to a single epitope not multi epitopes. ..
  33. Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Raphael Dolin, Dean for Clinical Programs, Harvard Medical School, will guide Dr. Barouch's development as an independent investigator. In addition, a committee of distinguished scientists will oversee his progress toward independence. ..
  34. Novel Adenovirus Vaccine Vectors for HIV/SIV
    Dan H Barouch; Fiscal Year: 2010
    ..abstract_text> ..
  35. Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV
    DAN BAROUCH; Fiscal Year: 2008
    ..The long-term objectives of these studies are to develop novel vaccine regimens that recruit APCs to the site of inoculation in animal models and to consider advancing the most promising strategies into clinical trials. ..
  36. IMMUNOREGULATION IN AIDS
    Norman Letvin; Fiscal Year: 2008
    ..3. Nondominant SHIV epitope-specific CTL populations. A. Breadth and magnitude. B. Functional repertoire. C. TCR repertoire. 4. Nondominant epitope-specific CTL and control of SIV replication. [unreadable] [unreadable]..
  37. 25th Annual Symposium on Nonhuman Primate Models for AIDS
    Christopher Miller; Fiscal Year: 2007
    ..This format has been successfully followed using NCRR support for the previous Annual symposium. [unreadable] [unreadable] [unreadable]..
  38. PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINE
    Christopher Miller; Fiscal Year: 2002
    ....
  39. Chimeric Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Within the two-year time frame of this award, sufficient data will be generated with candidate chimeric rAd vaccines to justify further vaccine/challenge studies in rhesus monkeys. ..
  40. Conference HIV Vaccine Development Progress & Prospects
    Norman Letvin; Fiscal Year: 2004
    ..abstract_text> ..
  41. DEVELOPMENT OF THE PRIMATE IMMUNOLOGY RESOURCE
    Christopher Miller; Fiscal Year: 2003
    ..This type of sustained support for assay development is required if immune studies in non-human primates are going to significantly advance in the near future. ..
  42. MVA/HIV-48: Potential Dual Vaccine for HIV and Smallpox
    Rama Rao Amara; Fiscal Year: 2003
    ..The project will be a collaborative undertaking between researchers at the CDC, the NIAID, and the NIAID HIV Vaccine Trial Network (HVTN ). The focus of this application is the quantification and phenotyping of responding T cells. ..
  43. Effect of DC-SIGNR Polymorphisms on HIV-1 Infection
    Tuofu Zhu; Fiscal Year: 2003
    ..These studies should assist in the identification of new therapeutic targets and strategies to protect against HIV-1 transmission and control disease progression. ..
  44. MECHANISMS OF ORAL SIV TRANSMISSION
    Ruth Ruprecht; Fiscal Year: 2003
    ..The data generated will help in formulating strategies to decrease the risks of oral HIV-1 transmission, including late virus transmission during breast feeding. transport and the roles of TC10 in cellular growth. ..
  45. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2007
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  46. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2004
    ....
  47. SIV delta vif DNA Vaccines with Cytokine Adjuvants
    Ellen Sparger; Fiscal Year: 2004
    ..Knowledge gained in this project on the SIV/macaque model will set the stage for evaluation of a DNA vaccine for preventing HIV-1 infection and AIDS in humans. ..
  48. FIVDELTAVIF DNA Vaccines with Cytokine Adjuvants
    Ellen Sparger; Fiscal Year: 2004
    ..Accordingly, knowledge gained in this project from this animal model will provide valuable information for evaluation of DNA vaccines for preventing HIV-1 infection and AIDS in humans. ..
  49. Development of a low inoculum SHIV challenge model
    Silvija Staprans; Fiscal Year: 2004
    ..Efficacy measures obtained in the low dose model could be compared to those obtained in 'high virus challenge' models, to see if the low-dose model detects efficacy that is masked by high virus inocula. ..
  50. Topical Microbicide Against SIV and Chlamydia
    Ashley Haase; Fiscal Year: 2007
    ....
  51. Cellular Immune Responses and AIDS Pathogenesis
    CYNTHIA DERDEYN; Fiscal Year: 2005
    ....
  52. Immune control of SIVagm replication in vivo
    JOERN SCHMITZ; Fiscal Year: 2009
    ..3. Assess whether abolishing both cellular and humoral adaptive immune responses will affect the course of SIVagm infection of African green monkeys. ..
  53. Dynamics of SHIV clade C and S mansoni coinfection
    Ruth Ruprecht; Fiscal Year: 2005
    ..These studies will provide valuable information whether parasitic helminth infections significantly alter HIV/AIDS pathogenesis and/or immunogenicity and efficacy of two different AIDS vaccine strategies. ..
  54. Cellular Immune Responses Induced by SIVdelta-vif plus IL-15 DNA Vaccine
    Ellen Sparger; Fiscal Year: 2008
    ..Findings from these studies may then be used for future design for more effective HIV-1 vaccines, as well as design for immunotherapeutics for HIV-1 infection. [unreadable] [unreadable] [unreadable]..
  55. MOLECULAR EVOLUTION OF MULTIPLY DELETED SIV IN VIVO
    Ruth Ruprecht; Fiscal Year: 2008
    ..These studies will deepen our understanding of the interaction between the rhesus monkey host, which is susceptible to lentiviral pathogenesis, and Rev-ind nef SIV, an apathogenic virus, even in neonates. ..
  56. PATHOGENESIS OF HIV INDUCED IMMUNODEFICIENCY
    Ashley Haase; Fiscal Year: 2008
    ..abstract_text> ..
  57. Minimal Levels of HIV-1 in Vaccinated & Exposed Persons
    Tuofu Zhu; Fiscal Year: 2007
    ..These studies should assist definition of virologic and immunologic characteristics required to attenuate and/or substantially control HIV-1 infection, a critical goal of AIDS vaccine development. ..
  58. New Model for NeuroAIDS Utilizing Monocyte-Derived HIV-1
    Tuofu Zhu; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..